Selecta Biosciences, Inc. (SELB) Bundle
Dive into the investor landscape of Selecta Biosciences (SELB) as the stock trades at $8.97 (last trade Monday, Dec 15, 17:15 PST) after an intraday open of $8.53, high of $9.21, low of $8.44 and volume of 291,051, while major holders such as FMR LLC report a roughly 10.2% stake and BlackRock, Vanguard, HOOPP, Geode and Artal appear among top institutional investors; notable moves include BlackRock adding 1.2M shares, Vanguard +300,000 shares, Renaissance initiating 500,000 shares, Timothy Springer boosting his holdings by 5.9% on April 11, 2025, Ally Bridge jumping 665.426% to 1.668% ownership, NanoDimension trimming to 2.470% (down 5.372%) and FMR trimming about 150,000 shares-contextualized by an average one‑year price target of $6.56 (a stated 465.27% upside), insider ownership of 31.20%, institutional ownership at 41.95% and a put/call ratio of 0.01, all of which paint a complex picture of confidence, rebalancing and speculative interest that this article will unpack in detail.
Selecta Biosciences, Inc. (SELB) - Who Invests in Selecta Biosciences, Inc. (SELB) and Why?
Selecta Biosciences, Inc. (SELB) is an equity listed in the USA market. Key intraday market snapshot (latest trade time Monday, December 15, 17:15:00 PST):| Metric | Value |
|---|---|
| Current Price | $8.97 |
| Change | $0.45 (0.05%) |
| Open (latest) | $8.53 |
| Intraday High | $9.21 |
| Intraday Low | $8.44 |
| Intraday Volume | 291,051 |
| Latest Trade Time | Monday, December 15, 17:15:00 PST |
- Institutional investors - hedge funds and biotech-focused mutual funds seeking asymmetric returns from clinical-stage pipeline catalysts or licensing deals.
- Retail investors - biotech enthusiasts/speculators targeting swing moves around trial readouts or partnership news.
- Long-term biotech/value investors - those betting on platform value and potential revenue from future commercial partnerships or royalties.
- Short-term traders - momentum players arbitraging intraday volatility; supported by the ~291k intraday volume indicating tradable liquidity.
- Pipeline upside - potential value from clinical readouts, platform validation, or milestone-driven licensing payments.
- Partnership potential - investors price in possible collaborations with larger pharma that could de-risk development and provide non-dilutive capital.
- Valuation relative to peers - speculative appeal if SELB trades at discounts to similar platform biotech companies.
- Event-driven strategy - trials, regulatory updates, or corporate transactions that can produce sharp re-ratings.
| Category | Data Point |
|---|---|
| Market access | U.S. exchange-listed equity; intraday liquidity shown by 291,051 volume |
| Price movement (intraday) | Range $8.44-$9.21; last trade $8.97 |
| Volatility considerations | Biotech typical event-driven volatility; intraday swing ~9% (high vs low) |
| Investor horizon | Mix of short-term traders and longer-term biotech investors |
| Key investor risks | Clinical failure, dilution from fundraising, partnership delays, regulatory setbacks |
- Company history, ownership, mission, and business model overview: Selecta Biosciences, Inc. (SELB): History, Ownership, Mission, How It Works & Makes Money
Selecta Biosciences, Inc. (SELB) Institutional Ownership and Major Shareholders of Selecta Biosciences, Inc. (SELB)
Selecta Biosciences, Inc. (SELB) draws a mix of large asset managers, pension funds, and specialized investment groups. The ownership profile signals institutional conviction in Selecta's platform and gene therapy pipeline, with major holders taking meaningful positions that influence liquidity, governance interest, and long-term capital support.- FMR LLC - ~10.2%: Large active manager positioning for growth exposure to Selecta's clinical and platform milestones.
- BlackRock, Inc. - ~8.6%: Passive and active strategies gaining biotech upside via scalable gene-therapy assets.
- Vanguard Group, Inc. - ~7.2%: Index and diversified fund exposure to biotech sector fundamentals.
- Healthcare of Ontario Pension Plan Trust Fund (HOOPP) - ~5.6%: Pension allocation seeking long-duration growth and downside mitigation.
- Geode Capital Management LLC - ~5.1%: Quant and index strategies with sizable benchmark-driven holdings.
- Artal Group S.A. - ~3.18%: Specialized investor with targeted biotech investments.
| Holder | Approx. Ownership % | Investor Type | Likely Investment Rationale |
|---|---|---|---|
| FMR LLC | 10.2% | Active Asset Manager | Growth exposure to Selecta's pipeline and potential value catalysts |
| BlackRock, Inc. | 8.6% | Asset Manager / ETF Provider | Broad biotech allocation, capture upside from gene therapy advances |
| Vanguard Group, Inc. | 7.2% | Index & Asset Manager | Passive/index exposure to sector plus selective active strategies |
| Healthcare of Ontario Pension Plan Trust Fund | 5.6% | Pension Fund | Long-term return generation and diversification into biopharma |
| Geode Capital Management LLC | 5.1% | Index/Quant Manager | Benchmark-driven allocation resulting in a material stake |
| Artal Group S.A. | 3.18% | Specialized Investment Group | Targeted investment in biotechnology innovation |
- Implications for shareholders: Concentrated institutional ownership can support secondary-market liquidity, provide informed oversight, and anchor long-term financing needs.
- Voting and governance: Holders with multi-percent stakes typically influence proxy outcomes and strategic dialogue with management and boards.
- Volatility considerations: Large institutional positions can amplify moves during rebalances, earnings, or clinical-readout events.
Selecta Biosciences, Inc. (SELB) Key Investors and Their Impact on Selecta Biosciences, Inc. (SELB)
Selecta Biosciences, Inc. (SELB) exhibits a concentrated institutional ownership profile where a handful of investors hold meaningful stakes that influence liquidity, governance dynamics, and strategic flexibility. The most recent quarter (as of September 30, 2023) shows a mix of stable long-term holders and active rebalancers - a combination that affects share price sensitivity to news, financing options, and board/management oversight.| Investor | Ownership % (Sep 30, 2023) | Quarterly Change (pp) | Implication |
|---|---|---|---|
| Artal Group S.A. | 5.642% | 0.000 | Steady anchor investor; stabilizes cap table |
| BlackRock, Inc. | 4.783% | -1.725 | Reduction likely from rebalancing; can add selling pressure |
| Vanguard Group, Inc. | 4.441% | +1.206 | Growing passive/active confidence; supports buy-and-hold flows |
| Mangrove Partners | 3.429% | 0.000 | Stable specialized investor; potential for constructive engagement |
| Madison Avenue Partners, LP | 2.475% | 0.000 | Consistent holder; limited near-term cap table disruption |
| NanoDimension, Inc. | 2.470% | -5.372 | Material reduction; indicates strategic portfolio shift or risk-off move |
- Voting and governance: Large, stable holders like Artal and Mangrove can influence governance outcomes and board composition in key votes.
- Liquidity effects: Combined top holders (approx. ~23% total) concentrate trading flow, making the stock more sensitive to institutional buying/selling.
- Capital raises: Presence of committed institutional investors improves prospects for equity financings or partnerships by signaling support.
- Volatility drivers: Reductions by major asset managers (e.g., BlackRock, NanoDimension) can coincide with quarter-end rebalancing or risk-management moves, causing short-term price swings.
- R&D runway and financing: Stability among top holders supports management in structuring financing rounds with less dilution pressure.
- Partnerships and M&A: Endorsement from specialized holders increases credibility in partnership negotiations.
- Market perception: Increasing stake by Vanguard (+1.206 pp) signals growing market confidence and can attract additional investors.
Selecta Biosciences, Inc. (SELB) Market Impact and Investor Sentiment
Investor moves over the past quarter indicate a mix of renewed institutional appetite and targeted insider conviction that is reshaping short-term sentiment around Selecta Biosciences, Inc. (SELB). The most notable actions - from a non-executive director's incremental purchase to large-scale fund reallocations - provide clues to both confidence in the company's pipeline and ongoing portfolio-level adjustments by major asset managers.- Timothy Springer (non-executive director) increased his holdings by 5.9% on April 11, 2025, signaling personal confidence in the company's near-term prospects and managerial alignment with shareholder value.
- BlackRock Inc. acquired an additional 1,200,000 shares in the last quarter, marking a material uptick in institutional ownership and suggesting conviction from a major passive/active allocator.
- Vanguard Group Inc. raised its stake by 300,000 shares, consistent with a bullish tilt from another large index/active hybrid manager.
- Renaissance Technologies LLC initiated a position with approximately 500,000 shares, indicating quantitative/hedge interest in SELB's risk/reward profile.
- FMR LLC (Fidelity Investments) trimmed its position by about 150,000 shares, likely reflecting portfolio rebalancing rather than a company-specific repudiation.
- Ally Bridge Group (NY) LLC increased holdings by 665.426% to reach 1.668% ownership, representing a strategic and significant re-weighting toward Selecta's equity.
| Investor | Reported Change | Shares Added/Removed | Noted Ownership / Change % | Date / Quarter |
|---|---|---|---|---|
| Timothy Springer (Non-exec Director) | Increase | Not disclosed (5.9% increase in holdings) | +5.9% (holding increase) | April 11, 2025 |
| BlackRock, Inc. | Increase | +1,200,000 shares | Material institutional accumulation | Last quarter |
| Vanguard Group, Inc. | Increase | +300,000 shares | Moderate increase | Last quarter |
| Renaissance Technologies LLC | New Position | ~500,000 shares | Initiated position | Last quarter |
| FMR LLC (Fidelity) | Decrease | -150,000 shares (approx.) | Reduced stake | Last quarter |
| Ally Bridge Group (NY) LLC | Large Increase | Not disclosed (665.426% increase) | Now 1.668% ownership | Last quarter |
- Increased holdings by BlackRock and Vanguard typically reduce free float available to retail traders and can support price stability if buying continues.
- Renaissance's initiation often signals algorithm-driven interest that can amplify intraday volatility around catalysts.
- Insider buying (Timothy Springer) is commonly interpreted by investors as a positive signal on upcoming data or corporate strategy.
- Ally Bridge's outsized percentage increase to 1.668% is notable for altering the shareholder base concentration and may reflect a targeted belief in Selecta's product pipeline.
- Fidelity's reduction appears consistent with rebalancing flows and does not, by itself, negate the broader pattern of increased institutional involvement.
Selecta Biosciences, Inc. (SELB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.